Van Malderen Kathleen, Hanning Nikita, Lambrechts Helen, Haverhals Tine, Van Marcke Silke, Ceuleers Hannah, De Man Joris G, De Winter Benedicte Y, Lamote Kevin, De Schepper Heiko U
Laboratory of Experimental Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Infla-Med Centre of Excellence, University of Antwerp, Antwerp, Belgium.
Department of Gastroenterology and Hepatology, Antwerp University Hospital, Edegem, Belgium.
Front Med (Lausanne). 2022 Aug 4;9:960000. doi: 10.3389/fmed.2022.960000. eCollection 2022.
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder for which no diagnostic tools are currently available. Patients are diagnosed using the Rome IV criteria and subtyped into a diarrhea, constipation, or mixed phenotype based on their dominant stool pattern. A recent development in the biomarker area is the analysis of volatile organic compounds (VOCs). The aim of this study was to evaluate the potential of VOCs as diagnostic and phenotypic biomarkers for IBS in breath and fecal samples.
Breath and fecal samples from IBS patients and healthy asymptomatic controls (HC) were analyzed with multicapillary column/ion mobility spectrometry (MCC/IMS) and classification models were created based upon VOCs and clinical characteristics.
Irritable bowel syndrome patients were differentiated from HC by means of volatile profiling in both breath and fecal samples with area under the curve (AUCs) of respectively 0.62 and 0.80. Patient subtypes could also be differentiated from each other with AUCs ranging between 0.65 and 0.78. Furthermore, VOC models could differentiate IBS patients based on clinical characteristics like psychological comorbidities and microbiota-influencing therapies.
This study is the first to demonstrate the use of VOC profiling with the help of MCC/IMS to differentiate IBS patients. Furthermore, the importance of clinical characteristics beside the dominant stool pattern in the differentiation of IBS patients was emphasized.
肠易激综合征(IBS)是一种慢性胃肠道疾病,目前尚无诊断工具。患者根据罗马IV标准进行诊断,并根据其主要粪便模式分为腹泻型、便秘型或混合型。生物标志物领域的一项最新进展是对挥发性有机化合物(VOCs)的分析。本研究的目的是评估VOCs作为IBS呼吸和粪便样本中诊断和表型生物标志物的潜力。
采用多毛细管柱/离子迁移谱法(MCC/IMS)分析IBS患者和健康无症状对照(HC)的呼吸和粪便样本,并基于VOCs和临床特征建立分类模型。
通过呼吸和粪便样本中的挥发性成分分析,肠易激综合征患者与HC得以区分,曲线下面积(AUCs)分别为0.62和0.80。患者亚型之间也可以相互区分,AUCs在0.65至0.78之间。此外,VOC模型可以根据心理共病和微生物群影响疗法等临床特征区分IBS患者。
本研究首次证明借助MCC/IMS进行VOC分析可区分IBS患者。此外,强调了在区分IBS患者时,除主要粪便模式外临床特征的重要性。